Is Vir Biotechnology (VIR) overvalued or fairly valued?

MarketChacha shows Vir Biotechnology's valuation in context — a forward P/E of about -4.1, a price-to-book of about 1.9 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Vir Biotechnology's revenue?

Vir Biotechnology reported revenue of $68.6M for FY2025, with net profit of $-438.0M, per official filings.

What is the share price of Vir Biotechnology (VIR)?

Vir Biotechnology last traded at $9.41 (-0.1% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Vir Biotechnology

VIR · NYSE · Healthcare · United States

$9.41-0.1%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:29 PM

Snapshot

TickerVIR

ExchangeNYSE

SectorHealthcare

IndustryBiotechnology

CountryUnited States

Employees367

HeadquartersSan Francisco, United States

Market cap$1.6B

P/B1.9

Volume1.08M

Websitewww.vir.bio

Filings tracked5

About Vir Biotechnology

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Profile as reported by Yahoo Finance.

Who owns it

Insiders6.6%
Institutions80.5%
Public & other12.9%

355 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.10.67%
Arch Venture Management, Llc7.66%
SB Investment Advisers (UK) LTD6.49%
Vanguard Portfolio Management LLC5.46%
GSK plc5.07%
State Street Corporation4.23%
Vanguard Capital Management LLC3.19%
Goldman Sachs Group Inc1.93%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

Forensic scorecard

Latest ROE of -57.2% is on the low side — the business earns a modest return on shareholder capital.

Net margin trend-713.7% → -638.9%

Margin has expanded by about 74.8 points — the business is getting more profitable.

Return on equity-57.2%

Latest ROE of -57.2% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $320,000 · EPS -0.81

Est. earnings growth +31.1%

Next fiscal year

Rev $112.9M · EPS -2.32

Est. earnings growth -69.2%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$4.1652-wk range$11.66

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Market cap

$1.6B

Day change

-0.1%

Fwd P/E

-4.1

P/B

1.9

Beta

1.62

Revenue (FY2025)

$68.6M

Net margin

-638.9%

ROE

-57.2%

Revenue CAGR (2y)

-10.8%

EPS (FY2025)

-3.16

Net profit (FY2025)

$-438.0M

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about VIR

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$68.6M	$-438.0M	-3.16	-638.9%	-57.2%
FY2024	$74.2M	$-522.0M	-3.83	-703.4%	-45.4%
FY2023	$86.2M	$-615.1M	-4.59	-713.7%	-38.7%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	—	$-125.7M	-0.85	—
2025Q3	$240,000	$-163.1M	-1.17	-67975.4%
2025Q2	$1.2M	$-111.0M	-0.80	-9139.9%
2025Q1	$3.0M	$-121.0M	-0.88	-3989.6%
2024Q3	$2.4M	$-213.7M	-1.56	-8979.7%
2024Q2	$3.1M	$-138.4M	-1.02	-4500.1%
2024Q1	$56.4M	$-65.3M	-0.48	-115.8%
2023Q3	—	$-163.4M	-1.22	—
2023Q2	—	$-194.8M	-1.45	—
2023Q1	—	$-141.0M	-1.06	—

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Executive/director change
SEC6/10/2026material
8-K — Executive/director change, Shareholder vote results
SEC5/28/2026material
10-Q filing
SEC5/7/2026
8-K — Results of operations, Exhibits
SEC5/6/2026material
8-K — Executive/director change
SEC4/10/2026material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.